TGFB1 and neoplasm: In vivo studies by Bandyopadhyay et al showed that the small TGFβ Inhibitor, TGFβ1 (1 mg/kg every alternative day) and Doxorubicin (4 mg/kg or 8 mg/kg once per 7 days) combination reduced tumor growth and lung metastasis by inhibition of epithelial-mesenchymal transition in the 4T1 orthotopic xenograft model in comparison to single treatments [35] and these results are consistent with those observed in our study.